Menu
Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1
Review on lipegfilgrastim
Authors Gasparic M, Leyman S
Received 15 September 2015
Accepted for publication 17 September 2015
Published 3 November 2015 Volume 2015:10(1) Pages 6863—6864
DOI https://doi.org/10.2147/IJN.S96413
Editor who approved publication: Prof. Dr. Thomas Webster
Maja Gasparic, Sophie Leyman
Teva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the Netherlands
Having read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we would therefore like to clarify what lipegfilgrastim actually is.
The description of lipegfilgrastim used in the original article was a “long-acting biosimilar filgrastim”.1 This description was subsequently amended in the corrigendum to “lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim”.2
Read the Corrigendum
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.